Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Oncternal Therapeutics In...

    NASDAQ: ONCT · Real-Time Price · USD
    0.53
    -0.16 (-23.63%)
    At close: Dec 02, 2024, 10:00 PM

    Oncternal Therapeutics Statistics

    Share Statistics

    Oncternal Therapeutics has 2.96M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 2.96M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 14.22%

    Shares Floating

    n/a
    		 2.71M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,650

    FTD / Avg. Volume

    n/a
    		 2.65%

    Short Selling Information

    The latest short interest is 138.62K, so 4.68% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 138.62K

    Short % of Shares Out

    n/a
    		 4.68%

    Short % of Float

    n/a
    		 4.86%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.8 and the forward PE ratio is null. Oncternal Therapeutics's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -0.8

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 40.15

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 1.05

    P/FCF Ratio

    n/a
    		 -0.98

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Oncternal Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.94, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 6.94

    Quick Ratio

    n/a
    		 6.94

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 0.14

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $29,074.07

    Profits Per Employee

    n/a
    		 $-1,462,185.19

    Employee Count

    n/a
    		 27

    Asset Turnover

    n/a
    		 0.02

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -93.8% in the last 52 weeks. The beta is 1.36, so Oncternal Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.36

    52-Week Price Change

    n/a
    		 -93.8%

    50-Day Moving Average

    n/a
    		 0.98

    200-Day Moving Average

    n/a
    		 4.96

    Relative Strength Index (RSI)

    n/a
    		 25.25

    Average Volume (20 Days)

    n/a
    		 62,268

    Income Statement

    In the last 12 months, Oncternal Therapeutics had revenue of 785K and earned -39.48M in profits. Earnings per share was -13.43.

    Revenue

    n/a
    		 785K

    Gross Profit

    n/a
    		 -28.97M

    Operating Income

    n/a
    		 -41.71M

    Net Income

    n/a
    		 -39.48M

    EBITDA

    n/a
    		 2.23M

    EBIT

    n/a
    		 -39.48M

    Earnings Per Share (EPS)

    n/a
    		 -13.43
    Full Income Statement

    Balance Sheet

    The company has 6.7M in cash and 318K in debt, giving a net cash position of 6.38M.

    Cash & Cash Equivalents

    n/a
    		 6.7M

    Total Debt

    n/a
    		 318K

    Net Cash

    n/a
    		 6.38M

    Retained Earnings

    n/a
    		 -197.78M

    Total Assets

    n/a
    		 15.6M

    Working Capital

    n/a
    		 8.99M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -32.16M and capital expenditures 0, giving a free cash flow of -32.16M.

    Operating Cash Flow

    n/a
    		 -32.16M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -32.16M

    FCF Per Share

    n/a
    		 -10.94
    Full Cash Flow Statement

    Margins

    Gross margin is -3690.19%, with operating and profit margins of -5313.89% and -5029.17%.

    Gross Margin

    n/a
    		 -3690.19%

    Operating Margin

    n/a
    		 -5313.89%

    Pretax Margin

    n/a
    		 -5029.17%

    Profit Margin

    n/a
    		 -5029.17%

    EBITDA Margin

    n/a
    		 284.71%

    EBIT Margin

    n/a
    		 -5313.89%

    FCF Margin

    n/a
    		 -4097.32%

    Dividends & Yields

    ONCT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ONCT is $10, which is 1786.8% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $10

    Price Target Difference

    n/a
    		 1786.8%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jan 8, 2024. It was a backward split with a ratio of 1:20.

    Last Split Date

    n/a
    		 Jan 8, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:20

    Scores

    Altman Z-Score

    n/a
    		 -30.51

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist